Wall Street brokerages expect Urovant Sciences Ltd (NASDAQ:UROV) to announce earnings of ($1.08) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Urovant Sciences’ earnings. The lowest EPS estimate is ($1.43) and the highest is ($0.90). The firm is expected to report its next earnings report on Monday, February 11th.
On average, analysts expect that Urovant Sciences will report full-year earnings of ($4.04) per share for the current financial year, with EPS estimates ranging from ($4.83) to ($2.82). For the next financial year, analysts expect that the company will post earnings of ($3.63) per share, with EPS estimates ranging from ($4.07) to ($3.18). Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Urovant Sciences.
Urovant Sciences (NASDAQ:UROV) last released its quarterly earnings results on Monday, November 12th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.93) by ($0.30).
UROV stock opened at $8.30 on Friday. Urovant Sciences has a 1 year low of $6.65 and a 1 year high of $14.32.
In related news, major shareholder Fund V. Lp Qvt bought 2,678,571 shares of the stock in a transaction that occurred on Monday, October 1st. The shares were bought at an average cost of $14.00 per share, for a total transaction of $37,499,994.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in UROV. FMR LLC purchased a new position in Urovant Sciences during the third quarter valued at $14,400,000. Sio Capital Management LLC purchased a new position in Urovant Sciences during the third quarter valued at $7,097,000. Perceptive Advisors LLC purchased a new position in Urovant Sciences during the third quarter valued at $5,552,000. BlackRock Inc. purchased a new position in Urovant Sciences during the third quarter valued at $4,574,000. Finally, Citadel Advisors LLC purchased a new position in Urovant Sciences during the third quarter valued at $2,209,000. Institutional investors own 7.18% of the company’s stock.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Recommended Story: Investing strategies using the yield curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.